CA2654008C - Polymeric biosurfactants - Google Patents

Polymeric biosurfactants Download PDF

Info

Publication number
CA2654008C
CA2654008C CA2654008A CA2654008A CA2654008C CA 2654008 C CA2654008 C CA 2654008C CA 2654008 A CA2654008 A CA 2654008A CA 2654008 A CA2654008 A CA 2654008A CA 2654008 C CA2654008 C CA 2654008C
Authority
CA
Canada
Prior art keywords
seq
group
process according
acylated biosurfactant
polymeric acylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2654008A
Other languages
English (en)
French (fr)
Other versions
CA2654008A1 (en
Inventor
Donald Owen
Lili Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Peptides Inc
Original Assignee
Therapeutic Peptides Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Peptides Inc filed Critical Therapeutic Peptides Inc
Publication of CA2654008A1 publication Critical patent/CA2654008A1/en
Application granted granted Critical
Publication of CA2654008C publication Critical patent/CA2654008C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2654008A 2006-06-01 2007-05-31 Polymeric biosurfactants Expired - Fee Related CA2654008C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80982506P 2006-06-01 2006-06-01
US60/809,825 2006-06-01
PCT/US2007/012799 WO2007143006A2 (en) 2006-06-01 2007-05-31 Polymeric biosurfactants

Publications (2)

Publication Number Publication Date
CA2654008A1 CA2654008A1 (en) 2007-12-13
CA2654008C true CA2654008C (en) 2015-11-24

Family

ID=38802034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2654008A Expired - Fee Related CA2654008C (en) 2006-06-01 2007-05-31 Polymeric biosurfactants

Country Status (7)

Country Link
US (1) US8586541B2 (https=)
EP (1) EP2037942B1 (https=)
JP (1) JP5697869B2 (https=)
KR (2) KR20090053752A (https=)
CN (2) CN105288581A (https=)
CA (1) CA2654008C (https=)
WO (1) WO2007143006A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045766A2 (en) * 2006-10-10 2008-04-17 True Look Skin Care Inc. Method for treating skin
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
ES2421262T3 (es) * 2007-11-30 2013-08-30 Evonik Goldschmidt Gmbh Composición para el cuidado personal y cosmética que contiene tetrapéptidos con las unidades CX1X2G, PX1X2P o PX1X2K
CN107028792A (zh) * 2008-05-29 2017-08-11 唐纳德·欧文 皮肤美容组合物中的寡聚生物表面活性剂
US8318678B2 (en) 2008-05-30 2012-11-27 Jan Marini Skin Research Cosmetic compositions
CN102203117A (zh) * 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
FR2944016B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
DK3777876T3 (da) * 2011-10-28 2023-10-30 Neostrata Company Inc N-acyldipeptid-derivater og anvendelser deraf
US20140349920A1 (en) * 2012-01-03 2014-11-27 Ruey J. Yu N-acylpeptide derivatives and their uses
US9808654B2 (en) 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
CN105189531B (zh) 2013-03-13 2020-02-21 安特易斯有限公司 用于皮肤复新的肽及其使用方法
EP2859883B1 (en) 2013-10-13 2019-05-15 Symrise AG Active mixtures comprising acylated oligopeptides and troxerutin
WO2016194760A1 (ja) * 2015-05-29 2016-12-08 ロート製薬株式会社 美容方法およびそれに用いる皮膚外用剤、並びに遊走付与剤、皮膚状態を向上させる美容方法に用いられる成分のスクリーニング方法
DE102015217504A1 (de) 2015-09-14 2017-03-16 Henkel Ag & Co. Kgaa Peeling mit Biotensiden
WO2018004224A2 (ko) 2016-06-27 2018-01-04 코스맥스(주) 신규 스포리치아과 미생물 및 그의 용도
CN107028987A (zh) * 2017-04-11 2017-08-11 成都吉氧屋科技有限公司 一种微生物黏附率调节剂及其应用
CN111759748B (zh) * 2020-08-14 2023-04-11 广州市乾相生物科技有限公司 一种抗衰老肽类组合物及其应用
KR102219317B1 (ko) * 2020-10-06 2021-02-24 엘앤피코스메틱 (주) 천연 보습인자를 이용하여 형성된 미셀 복합체를 포함하는 화장료 조성물의 제조방법 및 이로부터 제조된 화장료 조성물
CN114957384B (zh) * 2022-04-14 2023-11-14 湖北泓肽生物科技有限公司 一种二肽-4的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
KR100279540B1 (ko) * 1992-07-29 2001-02-01 슈테펜 엘.네스비트 펩티드 폐 계면활성제 및 치료용 혼합물
WO1998015179A1 (en) * 1996-10-08 1998-04-16 University Of Washington Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
GB9809084D0 (en) * 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
FR2783169B1 (fr) * 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6492326B1 (en) * 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US6875744B2 (en) * 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
KR100891157B1 (ko) * 2001-03-28 2009-04-07 헬릭스 바이오메딕스, 인코포레이티드 짧은 생물활성 펩티드 및 그것들의 사용 방법
FR2826266B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un inhibiteur de metalloproteinases matricielles
JP2004323401A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
US7863417B2 (en) * 2003-05-08 2011-01-04 Dsm Ip Assets B.V. Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure
JP4256389B2 (ja) 2003-11-17 2009-04-22 セダーマ テトラペプチドとトリペプチドの混合物を含む組成物
FR2865639B1 (fr) 2004-01-29 2007-10-19 Oreal Procede de preparation d'une composition de traitement cosmetique a partir de fluide sous pression, et d'acides amines, de peptides et de proteines

Also Published As

Publication number Publication date
JP5697869B2 (ja) 2015-04-08
CN105288581A (zh) 2016-02-03
US8586541B2 (en) 2013-11-19
CA2654008A1 (en) 2007-12-13
KR101552453B1 (ko) 2015-09-11
WO2007143006A3 (en) 2008-02-28
WO2007143006A2 (en) 2007-12-13
EP2037942B1 (en) 2014-09-03
KR20140097340A (ko) 2014-08-06
EP2037942A2 (en) 2009-03-25
KR20090053752A (ko) 2009-05-27
US20100144643A1 (en) 2010-06-10
CN101600441A (zh) 2009-12-09
EP2037942A4 (en) 2012-04-25
JP2009538917A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
CA2654008C (en) Polymeric biosurfactants
JP6230566B2 (ja) 皮膚化粧用組成物におけるオリゴマーバイオサーファクタント
CA2751436C (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions
AU2008271875B2 (en) Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same
US7977308B2 (en) Lys-Thr dipeptides and their use
Lintner Peptides and proteins
KR101264441B1 (ko) 올리고펩티드 및 그의 화장용 용도
WO2024170606A1 (en) Cyclic peptides with anti-aging efficacy
EP4188319A1 (en) Cosmetic or dermatological peptide-based treatment of the skin and its integuments
Namjoshi Development of Novel Carriers for Transdermal Delivery of Peptides
HK1162540B (en) Peptides for use in cosmetic or pharmaceutical treatment of the skin, mucous membranes and/or scalp

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831